Clozapine Service Standards
|
|
- Sydney Black
- 5 years ago
- Views:
Transcription
1 Clozapine Service Standards Policy Number: MHP SUM Oct 2013 Implementation Date: Nov 2013 First Review Date: Nov 2015 Review Frequency: Bi-Annual The MHS Clozapine Review Group is responsible for monitoring the policy 1
2 Clozapine Service Standards Contents Background Registration Prescribing Dispensing Monitoring Communication Information Governance Appendices In patient Clozapine initiation flowchart Standard titration regimes Prescribing Clozapine in special circumstances Protocol for the management of Clozapine patients who stop smoking Clozapine Out patient prescription Community pharmacy consent form Clozapine plasma monitoring Options for initiation of Clozapine Developed by MHS Clozapine Review Group Date approved: 9/10/13 Date of first review: 2
3 Clozapine Service Standards NHS Greater Glasgow & Clyde Background The second generation antipsychotic, clozapine, is the gold standard drug of choice for treatment resistant schizophrenia. Due to its serious side effect profile and licensing restrictions there are systems and criteria that must be met to ensure its safe use. This document details the standards mental health services in NHS Greater Glasgow & Clyde are expected to meet when using Clozapine regardless of the care setting. The standards consist of the following sections 1. Registration 2. Prescribing 3. Dispensing 4. Monitoring 5. Communication 6. Information Governance 7. Appendices 1. Registration 1.1 All patients, prescribers and pharmacy departments must be registered with the monitoring service associated with the contracted clozapine supplier for NHS Scotland. The registration process is summarised in appendix Clozapine may not be prescribed or dispensed until the registration process for a patient is complete. Forms for registering patients, prescribers, pharmacies, pharmacy staff and proxies are available on the ZTAS website ( 1.3 The patient s consultant psychiatrist is responsible for their registration. 1.4 Once a patient is registered for clozapine the patient should be given the "community pharmacy consent form" by their named nurse/cpn and asked to complete if they agree to their community pharmacist being informed that they are now receiving clozapine. Completed forms (appendix 6) should be returned to the address on the consent form. 2. Prescribing 2.1 All consultant psychiatrists prescribing clozapine will be registered with the current clozapine monitoring service. 2.2 Clozapine will be prescribed by or under the supervision of a consultant psychiatrist in accordance with the licensed indications for the drug. Any unlicensed prescribing of clozapine must be notified to and agreed with the clozapine monitoring service (e.g. re-challenge following a red result, concomitant treatment with chemotherapy). See appendix For in patients the approved standard titration regimes, including a blank format for bespoke regimes (available via the following link and in appendix 2a & b) will be used to initiate clozapine therapy. nagement/pages/rx_guidelines.aspx For out patients the titration regime indicated in the Options for Initiation of Clozapine document will used. When a patient is discharged from hospital a Clozapine out-patient prescription (appendix 5) must be sent to pharmacy along with the discharge prescription. All changes to clozapine prescriptions must be communicated to pharmacy immediately. 3
4 3. Dispensing NHS Greater Glasgow & Clyde 3.1 All pharmacy departments dispensing clozapine will be registered with the current clozapine monitoring service. Each registered clozapine pharmacy will have a registered clozapine pharmacist who is responsible in conjunction the Mental Health Sector Chief Technician for ensuring clozapine dispensing standards are met. 3.2 Clozapine will be dispensed in accordance with the systems and rules dictated by the marketing authorisation (license) and the clozapine monitoring service. 3.3 Each dispensary will have standard operating procedures describing the dispensing process. These will cover The roles and responsibilities of staff Staff training Dispensing procedures Use of the ZTAS system Quarantine processes Delivery schedules Communication If there is no valid blood result clozapine prescriptions will not be released from quarantine. 4. Monitoring 4.1 All patients prescribed clozapine will be monitored to the level described in the marketing authorisation and the clozapine monitoring service manual. Monitoring will be undertaken at ward level for in patients and in clozapine clinics or their equivalent for out patients. 4.2 Staff working in clozapine clinics and wards will receive training on the relevant clozapine systems e.g. ZTAS and the clinical use of the drug. A training package is available from pharmacy on request and a Learnpro unit is in development. All staff within clozapine clinics will have proxy access to the monitoring services web site. 4.3 Each clozapine clinic will have written Standard Operating Procedures describing all aspects of their function e.g. The scope of the service. Clozapine services will have a geographic rather than specialty remit i.e. they serve all clozapine patients within a defined catchment area. Locations & timings Staff & grades involved Did not attend procedures Amber result protocols Red result protocols Prescription collection procedures Use of the monitoring system web site 4.4 Full blood counts Patients on clozapine will have full blood count measurements taken to the following schedule Baseline for registration Weekly For a minimum of 18 weeks from start Fortnightly From the end of weekly monitoring up to a minimum of 52 weeks Every 4 weeks For as long as treatment continues post 52 weeks 4
5 Twice weekly Daily NHS Greater Glasgow & Clyde If an amber result is obtained. Continue until green If a red result is obtained. Continue until two successive green results Note: Patients may only progress from weekly to fortnightly or fortnightly to 4 weekly full blood counts if authorised by the clozapine monitoring service. Clozapine clinics and wards must have reliable processes for ensuring clozapine full blood counts are taken as scheduled. Full blood counts are normally sent to the clozapine monitoring service s laboratory for analysis. If samples are analysed locally it is the responsibility of the ward or clozapine clinic to transmit the result to the clozapine monitoring service. Clozapine discontinuation full blood count monitoring will be undertaken as described in the ZTAS manual. 4.5 Physical Health Monitoring All patients on clozapine, regardless of setting, will be offered monitoring for physical health problems to the standards described in the table on the following page. Clear communication and joint working between mental health services and primary care will be required to ensure any physical health issues identified are appropriately managed. The standards below are those produced national by SGHD in
6 Parameter/test Frequency Action if outside reference range Full Blood Count Follow manufacturer s mandatory protocol BMI Baseline, weight during initiation, 3 monthly for 1 year, then annually. Offer lifestyle advice. Plasma glucose (fasting) Baseline, at 1 month, then from 3 months, 3 monthly up to 1 year, then 6 monthly Offer lifestyle advice. Obtain HbA 1c. Consult with GP and/or specialist as appropriate. Blood lipids Baseline, 3 monthly for 1 year, then 6 monhtly. Blood pressure Baseline and as per initiation protocol, 3 monthly for 1 year, then annually. Also following changes. Baseline and as per initiation protocol, at 3 months, then annually Offer lifestyle advice and consult with GP and/or specialist for consideration of treatment e.g. statin therapy as appropriate. If hypotensive:.consider slower titration or reduction If Hypertensive: Offer lifestyle advice and consult with GP and/or specialist for consideration of treatment. Consider slower titration or reduction. If tachycardia persistent, observe for other indicators of myocarditis or cardiomyopathy. ECG Baseline, at 3 months and then annually. Act on abnormality according to significance, clinical indication. Refer to cardiologist if in doubt. Urea & electrolytes Baseline then as clinically indicated. Investigate as clinically appropriate. Liver function tests Baseline then annually or more frequently if clinically indicated. Investigate as clinically appropriate. Side-effects GASS for Clozapine ocognised sideeffect questionnaire for antipsychotic medication during initiation and regularly thereafter, with general side-effect enquiry at least at any point of blood sampling, with specific reference to constipation As clinically appropriate. Smoking status On initiation and at regular intervals thereafter, at least annually. Warn patient regarding effect of changes in smoking status. Check Clozapine level and GASS for Clozapine if change of status. Women of reproductive age Pregnancy/contraceptive status on initiation and at regular intervals thereafter, at least annually In all cases: Pre-pregnancy discussion of pregnancy intentions. Offer advice/signposting on contraception. Early discussion of options if unplanned pregnancy. 4.6 Side effect monitoring Clozapine clinics and wards will perform additional side-effect monitoring relevant to clozapine as a matter of routine. This will include Blood pressure Constipation Hypersalivation 6
7 Sedation Incontinence Signs of neutropenia sore throat, temperature & flu like symptoms Fits, faints & funny turns Clinical observation and the Glasgow Antipsychotic Side-effect Scale clozapine variant should be used for this. GASS should be undertaken every 6 months and one month after a change. Side-effect assessments will be recorded formally and reported systematically to the multi-disciplinary team. 4.7 Clozapine plasma level monitoring Clozapine clinics and wards will perform clozapine plasma level monitoring in line with MHS guidance at the request of a consultant psychiatrist. The main indications for clozapine plasma level monitoring are To monitor compliance In poor responders after an adequate trial especially prior to consideration of augmentation strategies If reduction is being contemplated To support the diagnosis of -related side effects* If a drug interaction is suspected Non-urgent investigation of suspected over If the patient s smoking status changes Measuring baseline levels during successful treatment to use as a reference point. *Side effects that are thought to be -related include; sedation, dizziness, hypersalivation, tachycardia, postural hypotension, constipation and seizures. Often these can be avoided/minimised by careful and slow escalation or alleviated by reducing the. The table in appendix 7 gives some advice on how to manage high clozapine plasma levels. 5. Communication 5.1 To ensure safe and effective use of clozapine there must be effective communication between the elements of the clozapine service. This includes the patient, their consultant psychiatrist, the pharmacy, clozapine clinics, wards and the clozapine monitoring service. Each clozapine patient s care plan will contain the relevant communication pathway with regards to their clozapine service and should include contact details for Consultant psychiatrist Clozapine pharmacy Clozapine clinic GP practice Community pharmacy GPs should be informed when Clozapine is prescribed or treatment is stopped and encouraged to add Clozapine to their prescribing records using the process developed by the prescribing support team. 5.2 The clozapine monitoring service (ZTAS) send alert faxes to the clozapine pharmacist and consultant psychiatrists. The table below lists these alerts and indicates the actions and responsibilities associated with them. 7
8 Alert fax Eligibility reminders Late reminders Discontinuation notification Non-Rechallengeable Amber warning Red Alert Downward trend/single drop Out of range warning high eosinophils or low platelets Actions & Responsibilities Pharmacy contact consultant & CMHT, ward to advise of move to fortnightly or monthly bloods & supplies. Consultant, ward or CMHT to organise urgent local FBC Pharmacy to cancel prescription Consultant, ward or CMHT to organise discontinuation bloods Consultant to place in case record indicates genuine red result therefore any future clozapine treatment unlicensed and must be approved by ZTAS Consultant, ward or CMHT to organise twice weekly FBC until green Clozapine treatment stopped. Pharmacy to contact consultant, ward or CMHT to confirm red alert. Consultant, ward or CMHT to organise urgent local FBC on a daily basis until two consecutive greens. Implement appropriate care as per ZTAS manual Consultant, ward or CMHT review recent blood history and physical status and if appropriate undertake additional blood tests Review patient urgently. FBC twice a week. High eosinophils stop clozapine until eosinophils less than 1. Monitor cardiac function including ECG. Low platelets stop clozapine until levels greater than Information governance 6.1 The clozapine monitoring service and their website (ZTAS) are essential to the safe use of clozapine. ZTAS must be notified immediately and then the clozapine pharmacy informed in the following circumstances to ensure the data they hold is up to date and accurate. Data item New registration or re-titration Apply & maintain clozapine PIMS alert Change of consultant Change of blood sampling location Treatment break Treatment discontinuation Off label treatment e.g. red re-challenge, concomitant chemotherapy Local blood sample Responsible person(s) for notifying ZTAS &/or clozapine pharmacy Medical staff CMHT staff - system still in development Medical staff Clozapine clinic or ward staff Medical staff or Clozapine clinic or ward staff Medical staff Medical staff Clozapine clinic or ward staff Forms for communicating with ZTAS are available on their website. 8
9 Perform all pre-treatment tests required for clozapine NHS Greater Glasgow & Clyde In patient clozapine initiation flowchart Appendix 1 Full blood count (FBC) with differential (valid for 10 days) ECG, baseline lipids, glucose, weight, LFTs & U&Es Register patient with ZTAS Registration form completed and signed by consultant. Forms are available on the log in page of the ZTAS website Faxed to ZTAS on Send titration regime & in patient prescription sheet to pharmacy (available on MH Staffnet pages)* Once confirmation of the registration is received from ZTAS, pharmacy will make an initial supply the amount of which will depend on the validity of the initial FBC. If registration FBC is no longer valid pharmacy will contact ward for an urgent local FBC. Commence patient on clozapine as described in the protocol Day 1 of the titration should ideally be a Monday and clozapine should not be initiated over a weekend. Monitor the patient as described in the titration regime. Day 2 take first on treatment FBC and send to ZTAS or local labs for analysis This blood test is essential to allow weekly dispensing of clozapine. Pharmacy will dispense the remainder on the titration regime to the appropriate schedule. Initiate weekly FBC for the patient preferably on a Monday or Tuesday to facilitate on going weekly dispensing each Friday This blood test is essential to allow on-going weekly dispensing of clozapine. The post titration regular should be prescribed on the in patient prescription sheet and this should be sent to pharmacy for a weeks supply of the post titration. Every time the is changed the altered in patient prescription sheet must be sent to pharmacy. *( ent/pages/rx_guidelines.aspx) Note: When a local blood sample is taken it is the responsibility of the ward to communicate the result of this sample to ZTAS and pharmacy. Do not commence a clozapine titration out of hours. 9
10 Clozapine Titration Regime Appendix 2a Name: Ward: CHI Number: Consultant: Administered Day Date 8am by 10pm mg mg 12.5mg mg 25mg 4 25mg 25mg 5 25mg 50mg 6 25mg 75mg 7 25mg 75mg 8 50mg 75mg 9 50mg 100mg 10 50mg 100mg 11 50mg 125mg 12 75mg 125mg mg 125mg mg 150mg mg 175mg Administered by Date Titration Commenced: Prescribing Doctor s signature: 10
11 Important Information for Nursing Staff NHS Greater Glasgow & Clyde This titration regime must also be prescribed by medical staff on the mental health prescription sheet as:- As per Clozapine titration regime Nursing staff must monitor for effect and side effects during titration [monitor blood pressure, pulse, respiration and temperature] and liaise with medical staff accordingly. * Should it be deemed necessary that a slower titration is required, this regime must be discontinued on the prescription sheet. Clozapine should then be prescribed as all other medications are prescribed and prescription dosages altered when required on the prescription sheet. Alternatively the blank titration regime may be used. After initial 15-day titration is complete, Clozapine can then be prescribed routinely on the prescription sheet. Prescribe as suggested by ZTAS recommendations: 8am 10pm Days mg 200mg Days mg 250mg Days mg 300mg Or as per. Consultant s prescription [Maintenance, reductions and increases thereafter as per. Consultants instructions] This regime is to be stapled to the reverse side of the current prescription kardex whilst in use then filed in case notes when complete. All nursing staff must be aware of side effects of Clozapine & to be alert for signs and symptoms of infections, refer to ZTAS guidance at all times. 11
12 Clozapine Titration Regime Appendix 2b Name: Ward: CHI Number: Consultant: Day Date 8am Administered by 10pm Administered by - Date Titration Commenced: Prescribing Doctor s signature: 12
13 Important Information for Nursing Staff This titration regime must also be prescribed by medical staff on the mental health prescription sheet as:- As per Clozapine titration regime Nursing staff must monitor for effect and side effects during titration [monitor blood pressure, pulse, respiration and temperature) as per options for initiation document (appendix 8) and liaise with medical staff accordingly. * Should it be deemed necessary that a slower titration is required, this regime must be discontinued on the prescription sheet. Clozapine should then be prescribed as all other medications are prescribed and prescription dosages altered when required on the prescription sheet. Alternatively the blank titration regime may be used. After initial 15-day titration is complete, Clozapine can then be prescribed routinely on the prescription sheet. The should be increased at a rate determined by the patient s response and their susceptibility to side effects. This regime is to be stapled to the reverse side of the current prescription kardex whilst in use then filed in case notes when complete. All nursing staff must be aware of side effects of Clozapine & to be alert for signs and symptoms of infections, refer to ZTAS guidance at all times. 13
14 Prescribing clozapine in special circumstances Appendix 3 Clozapine is an effective therapy for treatment resistant schizophrenia. Unfortunately it can cause neutropenia and agranulocytosis and consequently there are mandatory registration and monitoring parameters in place to support the safe use of this drug. As a general rule, clozapine should not be prescribed in combination with other drugs known to suppress white blood cell production e.g. carbamazepine, chloramphenicol, co-trimoxazole, penicillamine, cytotoxic agents and depot antipsychotics. However, it is acknowledged that occasionally some patients who are treated with clozapine may need to receive short term or episodic treatment with otherwise contra-indicated agents e.g. chemotherapy or interferon. In such cases if there would be significant detriment to the patient s health from discontinuing clozapine then, subject to approval from the clozapine monitoring service, a special treatment plan may be agreed to allow concomitant treatment. Essentially, this plan recognises that the suppression in white blood cells is due to the special treatment and not the clozapine and adjusts the monitoring requirements accordingly. The following describes the steps to be followed should such circumstances arise 1. As soon as a consultant psychiatrist becomes aware that their patient may be about to start a course of treatment with chemotherapy, interferon treatment or similar drugs they should contact their local clozapine dispensary and ZTAS (clozapine monitoring service) to make them aware of this. 2. In conjunction with the doctor responsible for the relevant treatment (oncologist, haematologist, gastro-enterologist etc) an agreed written treatment plan should be developed containing the following details (please see note 1 from the ZTAS SOPs below) The indication for the required treatment The drug being used The likely treatment course with a provisional end date The likely impact of this treatment on clozapine haematological factors (white cells, neutrophils and platelets) The haematological factors threshold below which it would not be appropriate to continue clozapine treatment (in the absence of any other treatment clozapine is stopped if the total white cell count falls below 3 and the neutrophils below 1.5). An indication of any other additional monitoring required 3. Once the treatment plan has been agreed locally it should be sent to ZTAS who will review it and then give their consent to a variation to the monitoring requirements for the patient. A copy of the treatment plan should also be sent to the local clozapine dispensary. 4. If any changes are made to the treatment plan they should be communicated to ZTAS and pharmacy as soon as possible. 5. ZTAS and pharmacy should be informed as soon as the treatment course ends, as the patient will then revert to standard clozapine monitoring. Andrew Walker Lead Clinical Pharmacist. May
15 Note 1 NHS Greater Glasgow & Clyde The following is additional advice from ZTAS. The ZTAS SOPs state that any re-challenge or decision to keep a patient from going to non-rechallengeable during concomitant treatment MUST be approved by a Consultant Haematologist. In this situation the treatment is not considered off-label. If a Consultant Haematologist does not provide/counter-sign the patient s treatment plan, the clozapine treatment will be considered off-label and a statement to the effect of the following must be signed by the Consultant Psychiatrist and the additional treating physician: The consultant should explicitly mention that he/she is willing to take full responsibility of the patient s medical situation for off-label treatment and that he/she absolves Leyden Delta from any liability should the patient s condition deteriorate during Zaponex treatment. Should the offlabel treatment occur as a temporary situation, e.g. use of concomitant medication that also effects blood results, ZTAS should be informed of the duration of the concomitant treatment. It is, of course, still possible for the treating team to complete a ZTAS Haematologist Consultation Form to be considered by our ZTAS Haematologist and Medical Advisor on a case-by-case basis. Appendix 4 Protocol for the management of clozapine patients who stop smoking Background 15
16 Tobacco smoke contains polycyclic aromatic hydrocarbons that increase the activity of certain hepatic enzymes especially CYP1A2. For patients who smoke this means that some drugs including clozapine undergo increased metabolism and consequently reduced plasma levels. This means a higher may be necessary to achieve a therapeutic effect. The effect of smoking is related i.e. the more cigarettes smoked the greater the enzyme induction. This also means that any reduction in the number of cigarettes smoked per day may result in increased clozapine plasma levels. This is worth bearing in mind should a patient begin to reduce their smoking in preparation for a quit attempt. When a patient stops smoking the increased enzyme activity reduces over a week or so. Once the enzyme activity returns to normal the of clozapine the patient is taking may be too high resulting in unwanted related side effects e.g. sedation, dizziness, hypersalivation, tachycardia, postural hypotension, constipation and seizures. The Maudsley Guidelines suggest the mean increase in plasma levels is 50% but as this is an average figure the actual increase could be lower or higher than this. For patients on clozapine who smoke and are also prescribed valproate, if they stop smoking the increase in clozapine plasma levels seen may be greater than that seen in patients not taking valproate. With the introduction of a smoke free environment in mental health patients will be compelled to stop smoking and therefore those on clozapine need to be carefully managed. This protocol describes the steps to be taken when a patient on clozapine stops smoking. 1. Take a clozapine plasma level before the patient stops smoking. Note this must be a trough level (take in the morning before the next clozapine ) and the results of clozapine plasma assays take about a week to come back from Magna Labs. 2. One week after stopping repeat the clozapine plasma level. During that initial week observe the patient for related side effects. If any emerge, consider reducing the clozapine gradually to around 75% of the pre-quit. If the is reduced take the post-quit plasma level one week after the is stable. 3. Depending on the result of the post-quit plasma level consider further reductions on a weekly basis. Subsequent plasma levels should be taken one week after any change. 4. Seek advice from pharmacy over interpretation of clozapine plasma assay results. It should be remembered that this ban on smoking is only enforceable whilst the patient remains in hospital. On discharge they may resume smoking. It is good practice to regularly ask patients about their smoking status and to review their clozapine accordingly. References: Maudsley Prescribing Guidelines in Psychiatry 11 th Edition 16
17 Patient s Name: Clozapine Registration Number CHI number (10 digits) NHS Greater Glasgow & Clyde CLOZAPINE OUT PATIENT PRESCRIPTION REQUEST FORM Consultant Collection address Professional Check by; Number: Appendix 5 START DATE* DRUG FORM DOSE MORN ING LUNCH TIME TEA TIME NIGHT STOP DATE* DATE QUANTITY SUPPLIED DISP BY CHECK BY A B C D E F * To be used during escalation (see guidance notes) Compliance aid required Y / N Date prescribed Doctor s signature Date to commence Doctors name (print) 17
18 Consent to Inform your Community Pharmacy (Chemist) That you are taking Clozapine Appendix 6 Most clozapine within Glasgow and Clyde is supplied to you from a hospital pharmacy. This means that the community pharmacy (chemist) you go to for all your other medication will not know that you are on clozapine medication. As the community pharmacist does not know you are taking clozapine they cannot do their normal job. This includes checking that all your medications are safe to take together and identifying possible side effects from taking clozapine. We would like to let your community pharmacy know that you are taking clozapine so that they can provide you with better care. We would also like to tell them what community psychiatric team you attend so they can contact the team if needed with any concerns they have about your health. You can consent to us telling the community pharmacy about this by completing the form below. You can choose which parts you want to consent to. Name (please print) Community Pharmacy used.. I give my consent to let my community pharmacy (chemist) know that I am taking clozapine medication Signature: Date:.. Community psychiatric team attended I give my consent to let my community pharmacy (chemist) know which community psychiatric team provides my care. Signature: Date:.. Please hand back to your nurse for them to return to Leverndale Pharmacy 18
19 When is it appropriate to measure clozapine plasma levels? To monitor compliance In poor responders after an adequate trial If reduction is being contemplated To diagnose -related side effects If a drug interaction is suspected Non urgent investigation of suspected over If the patient s smoking status changes Measuring baseline levels during successful treatment to use as a reference point NHS Greater Glasgow & Clyde How do I interpret the result? Level = 0mg/L Level <0.35mg/L Review patient if >50mg/day suggests no clozapine taken for up to a week before sampling If response good maintain current. If response poor review and address issue of compliance. If compliance OK, consider cautious increase and repeat assay after 1 week. Level mg/L If response good maintain current. If side effects present and are serious or persistent consider cautious reduction. If response poor and there has been an adequate trial consider cautious increase or augmentation Level mg/L If response good review current and consider cautious reduction if mental state allows. Consider sodium valproate as prophylaxis against seizures. If response poor cautiously reduce to bring level down below 0.6mg/L. Monitor mental state and repeat level at least 1 week after reduction. Level mg/L If response good with no signs of toxicity review and consider cautious reduction to bring level below 1 and possibly below 0.6mg/L. Consider sodium valproate as prophylaxis against seizures. If response poor cautiously reduce to bring level down below 1 and possibly below 0.6mg/L. Monitor mental state and repeat level at least 1 week after reduction. Plasma clozapine may continue to rise in the short term even after reduction commenced. Level 2mg/L & above If response good with no signs of toxicity URGENT REVIEW and consider cautious reduction if mental state allows. Consider sodium valproate as prophylaxis against seizures. If response poor URGENT REVIEW and reduction. If patient in the community consider admitting. Stop clozapine for 24 hours and re-start at 75% of last and reduce by 25mg per week to bring plasma clozapine below 1 and possibly below 0.6mg/L. Monitor mental state and repeat level at least 1 week after reduction. Plasma clozapine may continue to rise in the short term even after reduction commenced. Note: Contact a clinical pharmacist for advice & help interpreting levels. 19
20 Options for the initiation of clozapine Background A review of clozapine services in NHS Greater Glasgow & Clyde undertaken in 2011 recommended that out patient clozapine initiation be adopted as standard. However whilst seeing this as potentially desirable the Governance group requested that an options paper be prepared describing a range of solutions for the initiation of clozapine treatment. This paper has been prepared by a subgroup of the MHS Clozapine Review Group and is endorsed by the overall group. The options described are those that services with appropriate resources, planning and co-ordination can implement. It should be noted these options relate to new patients starting clozapine not re-titration of existing patients after a treatment break. Standards The group believes that it is a fundamental standard that the minimum monitoring parameters must apply to all patients starting clozapine regardless of where that might be. The monitoring will be mandatory and that requirement has influenced the options described in this document. The monitoring standards are as follows 1. Mandatory full blood count monitoring as required by the clozapine marketing authorisation. 2. Cardiac parameters as describe in the following table Day Parameters Frequency 1 erature, pulse, blood pressure (standing & lying) Immediately before then hourly for 6 hours 2 erature, pulse, blood pressure (standing & lying) Immediately before then after 2 and 6 hours 3-15 erature, pulse, blood pressure (standing & lying) Immediately before then after 6 hours It is also recommended that patients be assessed daily for evidence of dizziness, drowsiness, hypersalivation, constipation and urinary problems. Any abnormal parameters or emerging side effects must be reported to medical staff immediately. For community based initiation, during days 1 & 2, it is advisable that the patient remain in the monitoring area, for the remainder of the titration they may leave and return after 6 hours for monitoring. If they leave they should be advised to contact the service immediately if they experience any unusual symptoms. Options The group believes there are three feasible options for the initiation of clozapine 1. Hospital admission. This is standard practice at present and will remain necessary for many patients. With the exception of ensuring in patient services observe the monitoring standards the group will not comment further on this option. 20
21 2. Shared Care This option represents a flexible solution that incorporates brief admission (of varying duration) and early transfer to a community based approach. Patient assessment, planning and properly resourced community services will be essential to the success of this option. The elements of this option are Pre-assessment, patient selection and registration within Community Mental Health Teams Short term admission to hospital. Discharge to community support when clinically appropriate (minimum of three days after commencing clozapine). 3. Community initiation Where patient assessment deems it appropriate clozapine treatment may be commenced in a community setting, this may be achieved either by attending a resource centre on a daily basis or in the patient s home. It is the responsibility of the community mental health team to ensure they can safely deliver this option within the resources that they have available. With this option treatment must always commence on a Monday. The following issues are associated with this option Patient assessment Resources staffing and infrastructure For options 2 & 3 where there is a community component to the titration there must be a named individual who is responsible for co-ordinating the process. Their role will include Communication with RMO, Pharmacy, the ward as appropriate Identifying who is seeing patient where and when Ensuring the patient and their carers/relatives have all the relevant information including information about the drug, services and how to get support routinely and in an emergency etc There is an expectation that community services within the CHP including Crisis or similar services will provide support to deliver community based clozapine initiation. Patient assessment/selection To be eligible for option 2 or 3 patients must be assessed against the following criteria Patients must meet the licensed indications for community clozapine initiation (see the Summary of Product Characteristics) Patients should be considered suitable for out patient care in view of their current symptoms and safety risk. A thorough clinical assessment will be undertaken to determine suitability. Prior to treatment patients should be counselled and given standard information on clozapine treatment (ZTAS patient booklet & Choice and Medication literature) and then give consent (documented in care notes) to clozapine treatment and blood testing. Details of information provided should be recorded in the care notes. Patients must be aware of and agree to the requirement for attendance at a local mental health base in some circumstances, for daily home visits or that admission to local mental health hospital may be 21
22 required. It is the responsibility of the multi-disciplinary team to ensure that patients are appropriately informed of the relevant aspects of Clozapine treatment. An adequately resourced healthcare team must be in place. Sites should consider their capacity to support community initiation. It is advised that the patient is not left alone during the first week of treatment. Ideally someone (family/social carer) should stay overnight with the patient during that period. Patients must be able to contact the clinical team and out of hours support at all times (for option 2 from discharge onwards). If they can t then admission is the only option. Community initiation will not be appropriate for patients with a history of diabetes, cardiac disease, seizures or neuroleptic malignant syndrome or where they continue to misuse alcohol or drugs. Mandatory pre-treatment screening will be undertaken by the community mental health team and is primarily a medical responsibility and will include Full medical history particularly: diabetes, cardiovascular, seizure, or haematological disorders. Smoking status, use of caffeine. Baseline measurement of mental state using a standardised tool e.g. CGI Full physical examination including: weight, pulse, temperature, and blood pressure (standing and lying), and recent electrocardiogram (ECG). Recent is defined as within the last 6 months assuming no change in cardiac status or risk factors. If anything has changed an ECG should be performed as part of the pre-assessment process. Baseline blood screening: full blood count including differential white cell count, liver function tests, random plasma glucose, lipids, blood pressure, pulse, weight, urea and electrolytes. Registration with the clozapine monitoring service currently ZTAS. Where any of the following circumstances apply titration in hospital is recommended - Patient has significant difficulties in tolerating regime - Patient continues to misuse alcohol/substances - Patient or carer requests Hospital admission due to deterioration in mental state - Titration cannot be fully undertaken due to service demands Prescribing Standard clozapine titration regimes are used for in patient services. The group recommends that a standard prescription be adopted for options 2 & 3. Due to the constraints of community initiation that regime will differ from the in patient regime and will be as follows Day Dose 1 Monday 12.5mg in the morning 2 Tuesday 25mg in the morning 3 Wednesday 37.5mg in the morning 22
23 4 Thursday 50mg in the morning 5 Friday 75mg in the morning 6 Saturday 75mg in the morning 7 Sunday 75mg in the morning 8 Monday 100mg in the morning 9 Tuesday 100mg in the morning & 25mg in the evening 10 Wednesday 100mg in the morning & 50mg in the evening 11 Thursday 100mg in the morning & 50mg in the evening 12 Friday 100mg in the morning & 75mg in the evening 13 Saturday 100mg in the morning & 75mg in the evening 14 Sunday 100mg in the morning & 75mg in the evening 15 Monday 100mg in the morning & 100mg in the evening Please note that for option 3 treatment must commence on a Monday. Implications & issue for each option Option Implications & issues Comments Hospital Admission Only issue is in delayed access Status quo option. to a bed for a planned admission Excessive delays could to initiate clozapine. raise issues with meeting waiting times for Community Shared care Team resources Environment Monitoring at weekends Systems development Support networks As for community option plus Planning & co-ordination Communication Delayed access to a bed treatment. Patient preference Appendix 1 Pre clozapine physical and baseline blood screening Date/sign Results Blood test; FBC U&E s LFT Random Glucose Lipids ECG History of?renal disease 23
24 ?liver disease?cardiac disease?neutropenia?agranulocytosis?bone marrow disorder?gi disease? PTE or DVT Epilepsy Active alcoholism Glaucoma erature Baseline weight & measured height Smoking status Pregnancy status List of medication/history of compliance Sort paperwork and complete ZTAS registration Diagnosis appropriate Confirm patients understanding, consent and commitment Complete clozapine titration prescription Fax first week s prescription to Leverndale pharmacy NHS Greater Glasgow & Clyde Suitable for community clozapine initiation; YES/NO Planned start date; Keyworker informed; Crisis team informed; Appendix 2 Patient Label with chi Treatment centre- CLOZAPINE CLINIC CONTACT INFORMATION 24
25 Telephone- NHS Greater Glasgow & Clyde Monday to Friday 9am to 5pm Out with these hours, in case of Emergency, Crisis Team- Out of Hours Service- Very common side effects are : Drowsiness Dizziness Fast heartbeat Constipation Increased production of saliva. You Must ; Tell doctor/nurse immediately before taking the next clozapine tablet: if you get signs of a cold, fever, flu-like symptoms, sore throat or any other infection. if you feel unwell in any way if you have constipation. 25
26 Clozapine initiation in-patient observation record Surname Forename Date of birth CHI number Consultant Appendix 3 Baseline Recordings Date Weight DAY 1 am 1 0 (1 hour post ) pm DAY 2 am pm DAY 3 am 6 0 pm DAY 4 am 6 0 pm DAY 5 am 6 0 pm DAY 5 am 6 0 pm 26
27 DAY 7 am 6 0 pm DAY 8 am 6 0 pm DAY 9 am 6 0 pm DAY 10 am 6 0 pm DAY 11 am 6 0 pm DAY 12 am 6 0 pm DAY 13 am 6 0 pm DAY 14 am 6 0 pm DAY 15 am 6 0 pm 27
28 Clozapine initiation community patient observation record Surname Forename Date of birth CHI number Consultant Appendix 4 Baseline Recordings Date Weight DAY 1 am 1 0 (1 hour post ) DAY 2 am DAY 3 am 6 0 DAY 4 am 6 0 DAY 5 am 6 0 DAY 6 am 6 0 DAY 7 am 6 0 DAY 8 am
29 DAY 9 am 6 0 DAY 10 am 6 0 DAY 11 am 6 0 DAY 12 am 6 0 DAY 13 am 6 0 DAY 14 am 6 0 DAY 15 am
Initiation of Clozapine Treatment Community Patients
Initiation of Clozapine Treatment Community Patients Who Should Read This Policy Target Audience All clinical staff working in the community N/A N/A Initiation of Clozapine Treatment for Patients in the
More informationIntegrated Care Pathway (ICP) for the. Management of clozapine COMMUNITY INITIATION
Document Reference MM 049 Integrated Care Pathway (ICP) for the Management of clozapine COMMUNITY INITIATION Surname Title Address Forenames Date of Birth RT/NHS number Care Co-ordinator GP CS number Consultant
More informationPolicy & Procedures Committee Date: 18 January 2018
Clinical SOP Out-patient Clozapine Initiation Procedure SOP Document Control Summary Status: Replacement supersedes Clozapine Policies and Procedures Version: v1.0 Date: October 2017 Hayley Smart Mo Azar
More informationIntegrated Care Pathway (ICP) for the. Management of clozapine INPATIENT INITIATION
Document Reference MM 048 Integrated Care Pathway (ICP) for the Management of clozapine INPATIENT INITIATION Surname Title Address Forenames Date of Birth RT/NHS number Care Co-ordinator GP CS number Consultant
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationSTARTING PATIENTS ON. AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia.
STARTING PATIENTS ON AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia. Indication: AA-CLOZAPINE (clozapine) is indicated in the management
More informationThe licensed indications for the use of Clozapine are:- Treatment resistant schizophrenia.
1. Introduction Future Directions CIC will support the use of the antipsychotic Clozapine in all appropriate cases. The purpose of this procedure is to set out the standards for Clinicians, Pharmacists,
More informationNorth Central London Medicines Optimisation Committee
North Central London Medicines Optimisation Committee Guidance for Pharmacy Staff Managing Clozapine For Patients Admitted to Acute Hospitals Disclaimer This guideline is registered at North Central London
More informationClaire Thomas, Deputy Chief Pharmacist. Tim Donaldson, Trust Chief Pharmacist. Contents. Section Description Page No.
Pharmacological Therapy Policy Practice Guidance Note Safe Prescribing of Clozapine V02 Version issued Issue 1 Jan 16 Issue 2 Nov 16 Planned review January 2019 PPT-PGN-05 Part of NTW(C)38 Pharmacological
More informationClinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents
Clinical High Dose Antipsychotic Prescribing Procedures Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation
More informationGENERAL PRACTITIONER (GP) SUPPORT PACK
Document Reference MM 050 Integrated Care Pathway (ICP) for the Management of clozapine GENERAL PRACTITIONER (GP) SUPPORT PACK One pack to be printed for each patient initiated on clozapine treatment,
More informationGuideline for the In-patient initiation of Clozaril (Clozapine) within CWPT
Guideline for the In-patient initiation of Clozaril (Clozapine) within CWPT Version: 1 Author: Ambreena Asghar Designation: Pharmacist Responsible Director: Sharon Binyon Approved By: Drugs and Therapeutics
More informationWestern Locality Shared care Information ~ Penicillamine, Rheumatology April 2013
Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Prescribing and/ or Monitoring of Antipsychotics Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside
More informationName of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008
Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately
More informationClozapine Prescribing and Monitoring Guideline
Document level: Trustwide (TW) Code: MP5 Issue number:6 Clozapine Prescribing and Monitoring Guideline Lead executive Authors details Type of document Target audience Document purpose Dr A Sivananthan
More informationClozapine Outpatient initiation
Clozapine Outpatient initiation 1. Introduction The licence for clozapine enables commencement of clozapine as an outpatient. Hospital admission for initiating clozapine has been recommended in the past
More informationClozapine intramuscular (IM) Guideline, inpatients only
SH CP 203 Clozapine intramuscular (IM) Guideline, inpatients only Summary: Guideline for use and monitoring of intramuscular clozapine treatment. Keywords: Target Audience: Clozapine, intramuscular, IM,
More informationDatix Ref:
Title Document Details Shared Care Agreement: Antipsychotics (Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine) Trust Ref No 2081-38933 Local Ref (optional) Main points the document
More informationClozapine Shared Care Protocol And Information For Oxfordshire GPs
Clozapine Shared Care Protocol And Information For Oxfordshire GPs There should be willing consent of all parties to enter into a shared care agreement. This includes patients (plus carers if necessary)
More informationPOLICY DOCUMENT. Pharmacy MMG/MPG. Approved By and Date Medicines Management roup March March 2016
POLICY DOCUMENT Document Title High dose and combination antipsychotic guidance Reference Number n/a Policy Type Prescribing and Treatment Guideline Electronic File/Location Clinical Resources/Pharmacy/Prescribing
More informationHYDROXYCARBAMIDE for Haematological conditions (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: HYDROXYCARBAMIDE for Haematological conditions (Adults) Indication: Hydroxycarbamide is an established treatment in haematological
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only)
E099 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and
More informationCLOZAPINE TREATMENT GUIDELINES MARCH 2017
CLOZAPINE TREATMENT GUIDELINES MARCH 2017 0 Policy title Clozapine treatment guidelines Policy PHA06 reference Policy category All clinical staff who deal with medication in the Trust. Relevant to Clinical
More informationNHS Grampian Guidance For Staff Working In The Mental Health Service For The Use Of High-Dose Antipsychotic Medication
NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS Date 20 th November 2014 Our Ref HDAT_MGPG/Nov14 Enquiries to Caroline Hind Extension 56088 Direct Line 01224 556088 Email caroline.hind2@nhs.net
More informationNorth of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines
\ North of England Cancer Network Policies and Procedures Standards for the Safe Use of Oral Anticancer Medicines NECN Oral Anticancer medicine Policy version 1.6 Page 1 of 17 Issue Date: Feb 2017 Contents
More informationNHS GG&C -Mental Health Services. Lithium Ward Bundle
Lithium Ward Bundle Lithium is a useful drug, particularly in the maintenance treatment of bipolar affective disorder, recurrent depression and self injurious behaviour. It is widely used and most patients
More informationHave you already tried different drugs for your schizophrenia? Here s another option you and your doctor may want to consider.
Have you already tried different drugs for your schizophrenia? Here s another option you and your doctor may want to consider. 1 Benefits of Clozapine Clozapine may work when other medications don t. Doctors
More informationShared Care Guideline for Olanzapine (Zyprexa )
Shared Care Guideline for Olanzapine (Zyprexa ) Development Process This guidance has been produced by Sarah Hudson Lead Pharmacist SWYPFT following an AMBER classification status of Olanzapine by the
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance
More informationDrug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:
More informationHigh Dose Antipsychotic Therapy (HDAT) guideline
Document level: Trustwide (TW) Code: MP18 Issue number: 2 High Dose Antipsychotic Therapy (HDAT) guideline Lead executive Medical Director Author and contact number Lead Clinical Pharmacist 01625 663 857
More informationHIGH DOSE ANTIPSYCHOTIC GUIDELINES (HDAT)
HIGH DOSE ANTIPSYCHOTIC GUIDELINES (HDAT) Document Reference Version Number 2.00 High Dose Antipsychotic Guidelines (HDAT) G376 Author/Lead Job Title Jackie Stark Principal Pharmacist Clinical Services
More informationEffective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )
Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) This shared care agreement outlines the ways in which the responsibilities
More informationClozapine, neutropenia and agranulocytosis, red alert management
Clozapine, neutropenia and agranulocytosis, red alert management The information in this document is not intended as a definitive treatment strategy, but as a suggested approach for clinicians. It is based
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationDocument ref. no: Trust Policy and Procedure. PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy
Document ref. no: Trust Policy and Procedure PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy For use in: For use by: For use for: Document owner: Status: All Clinical Areas
More informationSHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) 1. Introduction This protocol describes how patients prescribed medicines for ADHD
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine
Ref No: E053 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and file
More informationPatient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists
Patient Group Direction for the Supply of Varenicline (Champix ) This Patient Group Direction (PGD) is a specific written instruction for the supply of varenicline to groups of patients who may not be
More informationAripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014)
1. Key Points. Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014) 1.1 Aripiprazole long acting injection (LAI) is licensed / indicated
More informationMethotrexate for inflammatory bowel disease: what you need to know
Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or
More informationNRT Voucher redemption scheme service specification
NRT Voucher redemption scheme service specification Updated March 2016 Review date March 2018 Page 1 of 7 1. Introduction The NRT voucher scheme is for NHS Fife stop smoking advisors who have been deemed
More informationSHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More informationPathology Service User Guide Haematology
Pathology Service User Guide Haematology St Richard s This section of the Pathology Service User Guide includes: Anticoagulant Therapy Information about the Anticoagulant Clinic Low Molecular Weight Heparin
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationPOLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE. September 2011
POLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE September 2011 WHSCT Policy for the safe use of oral methotrexate in secondary care Page 1 of 8 Policy Title Policy for the safe use of oral
More informationPaliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016)
Paliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016) 1. Key Points 1.1 Paliperidone palmitate 3-monthly long-acting
More informationWestern Locality Shared care information ~ Azathioprine and Mercaptopurine
The following guidelines are currently under review. In the interim, the guidelines remain valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they
More informationNORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE
NORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE http://www.devonpct.nhs.uk/treatments/ne_devon_shared_care_guidelines.aspx#a Azathioprine Treatment of rheumatological conditions
More informationSafe Use of Latex Policy
Safe Use of Latex Policy Lead Manager: Andy Crawford- Head of Clinical Governance Responsible Director: Jointly by: Director of Human Resources Medical Director Approved by: Jointly by: Health & Safety
More informationThis shared care protocol covers when atypical antipsychotics are prescribed for the treatment of
SHARED CARE PROTOCOL for ATYPICAL ANTIPSYCHOTICS SCOPE Greater Manchester West Mental health NHS Foundation Trust Bolton Primary Care Trust Salford Primary Care Trust Trafford Primary Care Trusts Issue
More informationPATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE GENERAL POLICY 2 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE 4 STANDING ORDER
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Lithium Treatment in Adults aged 18-65 years Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside & Glossop
More informationProcedure and Guidance for the use of Clozapine
Procedure and Guidance for the use of Clozapine Version: 2.1 Ratified by: Drugs & Therapeutics Group Date ratified: April 2015 Date issued: August 2015 (minor amendment Dec 15) Next Review Date: August
More information02/GMS/0030 ADULT EPILEPSY SERVICE CCP for General Medical and Surgical POOLE HOSPITAL NHS FOUNDATION TRUST
Service Specification No. Service Commissioner Leads 02/GMS/0030 ADULT EPILEPSY SERVICE CCP for General Medical and Surgical Provider Lead POOLE HOSPITAL NHS FOUNDATION TRUST Period 1 April 2013 to 31
More informationPRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD)
PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD) For the latest information on interactions and adverse effects, always consult the latest version of the Summary of
More informationIntegrated Community Diabetes Services (ICDS) GP Referral Guide Version 3 - October 2014
Integrated Community Diabetes Services (ICDS) GP Referral Guide Version 3 - October 2014 Introduction The Integrated Community Diabetes Service (ICDS) will deliver high quality care to individuals who
More informationSULFASALAZINE (Adults)
Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn
More informationConduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA)
E102 Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) Patient details Name: Date of birth: NHS number: Contact details Specialist:
More informationDear Colleague GENERAL OPHTHALMIC SERVICES OPTOMETRY INDEPENDENT PRESCRIBING. Summary
NHS: PCA(O)(2013)4 Health and Social Care Integration Directorate Primary Care Division Dear Colleague GENERAL OPHTHALMIC SERVICES OPTOMETRY INDEPENDENT PRESCRIBING Summary 1. This letter advises NHS Boards
More informationGUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA)
GUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA) Introduction Aripiprazole long-acting injection (LAI)is licensed for the maintenance treatment of adult patients with schizophrenia
More informationDear Colleagues, NATIONAL STANDARD FOR MONITORING THE PHYSICAL HEALTH OF PEOPLE BEING TREATED WITH LITHIUM
Directorate of Chief Medical Officer T: 0131-244 6930 E: john.mitchell4@gov.scot Dear Colleagues, NATIONAL STANDARD FOR MONITORING THE PHYSICAL HEALTH OF PEOPLE BEING TREATED WITH LITHIUM Lithium is a
More informationGuidance for Pharmacists on Safe Supply of Oral Methotrexate
Guidance for Pharmacists on Safe Supply of Oral Methotrexate Pharmaceutical Society of Ireland Version 2 January 2015 Contents 1. Introduction 2 2. Methotrexate 2 3. Guidance 2 3.1 Patient Review 2 3.2
More informationPrescribing Framework for Rivastigmine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationNHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Carbamazepine. For the Treatment of Pain
NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Carbamazepine For the Treatment of Pain This information is not intended to replace your doctor s
More informationPrescribing Framework for Galantamine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Galantamine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationPATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets. By: Accredited Pharmacists
PATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets By: Accredited Pharmacists In: Community Pharmacies in [insert area] accredited by [insert council] It is the responsibility of
More informationAzathioprine and Mercaptopurine
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationCOALINGA STATE HOSPITAL NURSING POLICY AND PROCEDURE MANUAL SECTION - Medications POLICY NUMBER: 510
COALINGA STATE HOSPITAL NURSING POLICY AND PROCEDURE MANUAL SECTION - Medications POLICY NUMBER: 510 Effective Date: August 31, 2006 SUBJECT: CARE OF THE INDIVIDUAL RECEIVING CLOZAPINE 1. GENERAL: Clozapine
More informationClozapine an introduction to treatment
Clozapine an introduction to treatment Pharmacy Department If at any time you have run out of tablets, or are concerned that you may run out, please contact the number below as soon as possible: A member
More informationWe have reviewed the Winter Planning guidance for 2011/12 and have applied the guidance, where relevant, within this refreshed plan.
NHS National Waiting Times Centre Winter Plan 2011/12 Introduction This plan outlines the proposed action that would be taken to deliver our key business objectives supported by contingency planning. This
More informationGood Practice Guidance on Covert Administration of Medication
Good Practice Guidance on Covert Administration of Medication This good practice guidance is intended to be used as a framework for care home managers and domiciliary care providers in drawing up their
More informationEssential Shared Care Agreement: Lithium
Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed
More informationGuidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting
ANTICOAGULANT SERVICE Guidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting Introduction Fast loading of warfarin carries a risk of over anticoagulation
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57 INDICATION: Attention deficit hyperactivity disorder (ADHD) as part of a
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
More informationPrescription of High Dose Antipsychotic Medication
Subject (M1) Title Medicine Prescription of High Dose Antipsychotic Medication Manual Mental Health Procedure No M1-P-2-MH Department Pharmacy Distribution All Author Rae McKnight Review 4 Reviewer Jonathan
More informationJob Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due
More informationMMG012 GUIDELINES FOR THE USE OF HIGH DOSE ANTIPSYCHOTIC MEDICATION
MMG012 GUIDELINES FOR THE USE OF HIGH DOSE ANTIPSYCHOTIC MEDICATION Page 1 of 16 Table of Contents Why we need this Policy... 3 What the Policy is trying to do... 3 Which stakeholders have been involved
More informationAll Saints First School Administering of Medicines Policy
All Saints First School Administering of Medicines Policy Success Indicators The following indicators will demonstrate the level of compliance with this policy and its procedures: a) Employees who are
More informationPolicy for Supporting. Children and Young People with. Diabetes in Education
Policy for Supporting Children and Young People with Diabetes in Education December 2011 POLICY FOR SUPPORTING CHILDREN AND YOUNG PEOPLE WITH DIABETES IN EDUCATION Contents 1. Introduction 2. Before a
More informationNPSA SAFER LITHIUM THERAPY GUIDELINES FOR NHS LANARKSHIRE
NPSA SAFER LITHIUM THERAPY GUIDELINES FOR NHS LANARKSHIRE Implementation Date Spring 2013 Review Date Spring 2016 NPSA Safer Lithium Therapy Guidelines for NHS Lanarkshire BACKGROUND On 1 st December 2009
More informationPROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE
PROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE BRIEF OUTLINE OF THIS PROCEDURE This procedure sets out the requirements for prescribing,
More informationStandard Operating Procedure: Early Intervention in Psychosis Access Times
Corporate Standard Operating Procedure: Early Intervention in Psychosis Access Times Document Control Summary Status: New Version: V1.0 Date: Author/Owner: Rob Abell, Senior Performance Development Manager
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Recognising and managing bipolar disorder in adults in primary care bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are
More informationfor adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services
The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service
More informationPATIENT GROUP DIRECTION
PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (CHAMPIX ) TO ADULTS OVER 18 YEARS OF AGE BY COMMUNITY PHARMACISTS UNDER THE PUBLIC HEALTH SERVICE - SMOKING CESSSATION SERVICE IN NHS HIGHLAND THE
More informationPATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN NHS LANARKSHIRE
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN NHS LANARKSHIRE (Approved May 2014 - Review Date May 2016) GENERAL POLICY PATIENT GROUP DIRECTION
More informationGuidance for Pharmacists on the Safe Supply of Non-Prescription Levonorgestrel 1500mcg for Emergency Hormonal Contraception
Guidance for Pharmacists on the Safe Supply of Non-Prescription Levonorgestrel 1500mcg for Emergency Hormonal Contraception Pharmaceutical Society of Ireland Version 4 December 2016 Updates made following
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationOlanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)
1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINES FOR PRESCRIBING OF METHYLPHENIDATE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN INDICATION Methylphenidate is generally regarded as a first line choice of treatment for
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationDrug and Alcohol Misuse Policy
Drug and Alcohol Misuse Policy MOHFC 22 Introduction 1. MOHFC recognises that alcohol and drug misuse related problems are an area of health and social concern. It also recognises that a member of staff
More informationClinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02.
Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: 08.01.15 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder
More informationAPOMORPHINE (Adults) Shared Care Guidelines DRUG:
Shared Care Guidelines DRUG: APOMORPHINE (Adults) Indication: Treatment of motor fluctuations in patients with Parkinson's disease which is not sufficiently controlled by oral anti-parkinson medication.
More information